Syneos Health has signed a new three-year agreement with Pfizer to provide global product development services to support Pfizer's portfolio. Pfizer has the right to extend the term for up to an additional two years. Financial details were not disclosed.
This agreement builds on a longstanding relationship where Syneos Health has provided services across the clinical and commercial continuum to support product development. The company will continue to provide a broad range of services customized to meet Pfizer’s goals across its portfolio, including full service and FSP solutions.
“Our ability to deliver deep therapeutic expertise, while bringing forward insights that can facilitate shorter and more efficient trials, has proven to be advantageous in our work with Pfizer,” said Paul Colvin, President, Syneos Health Clinical Solutions. “This new agreement allows us to continue our collaboration to deliver flexible and innovative solutions. We are pleased to expand our Pfizer relationship to optimize their portfolio and deliver on our shared purpose to change patients’ lives.”